Yumin Wu

                                                                                                 Research Associate Professor

She obtained a doctorate degree from Jiangsu University in 2017. From 2021 to 2024, she was engaged in postdoctoral research work at Soochow University. In 2024, she joined the Institute of Functional Nano & Soft Matter at Soochow University and was appointed as a research associate researcher.

Research Areas: Tumor and Inflammatory Immunity, Synthetic Biology, Gene Editing.

Main achievements and contributions:

She is devoted to the research related to the mechanisms and therapies in the field of tumor immunity. She is engaged in designing and developing biomaterials that can regulate the tumor immune microenvironment and promote immune responses. Her work mainly focuses on the research of utilizing genetically engineered bacteria to regulate the tumor and inflammatory immune microenvironments. She has already developed various genetically engineered bacteria with the capabilities of regulating the tumor immune microenvironment and killing tumors. She has published over 10 papers in internationally renowned academic journals such as Nature Communications, ACS Nano, and Biomaterials as either the first author or the corresponding author. She has also presided over several projects, including the National Natural Science Foundation of China Youth Science Foundation, the General Program of China Postdoctoral Science Foundation, and the Jiangsu Postdoctoral Research Project.

Awards:

· 2022 Jiangsu Excellent Postdoctoral Project

Representative papers

1. Wu Y, Liu B, Yan Y, Chen M, Zhu Y, Liu N, Dong Z, Feng L*, Liu Z*, Thermal-responsive activation of tumor-homing engineered bacteria to trigger robust antitumor immunity post ablation therapy. Nature Communications (In Press). 

2. Liu B, Wang K, Li Q, Xiao Z, Chen Z, Zhang Y, Wu Y, Xu Y, Wu Y*, Liu Z*. Engineered VNP20009 expressing IL-15&15Rα augments anti-tumor immunity for bladder cancer treatment. Biomaterials. 2024 Nov 6; 315: 122951. 

3. Ge L, Guo H, Zhou W, Shi W, Yue J, Wu Y*. Manganese-mediated potentiation of antitumor immune responses by enhancing KLRG1+  Macrophage function. Int Immunopharmacol. 2024 Nov 15;141: 112951.

4. Wu Y, Li Q, Yan Y, Hao Y, Wang C, Liu B, Zhu Y, Liu Z*, Feng L*. Gel-mediated recruitment of conventional type 1 dendritic cells potentiates the therapeutic effects of radiotherapy. Biomaterials. 2024 Mar; 305: 122470.

5. Yue J, Guo H, Yang X, Xu P, Ma J, Shi W*, Wu Y*. Combination of IL-33 with PD-1 blockade augment mILC2-mediated anti-tumor immunity.  Cancer Immunol Immunother. 2024 Mar 2;73(4):65.

6. Wu Y, Wang C, Yan Y, Hao Y, Liu B, Dong Z, Chen M, Zhu Y, Liu N, Feng L*, Liu Z*. Efferocytosis Nanoinhibitors to Promote Secondary Necrosis and Potentiate the Immunogenicity of Conventional Cancer Therapies for Improved Therapeutic Benefits. ACS Nano. 2023 Sep 26;17(18):18089-18102.

7. Yue J, Guo H, Xu P, Ma J, Wu Y*. Activation of the GPR35 on ILC2 drives immunosuppression to promote lung cancer progression. Am J Cancer Res. 2023 Jun 15;13(6):2426-2438.

8. Wu Y, Feng L*. Biomaterials-assisted construction of neoantigen vaccines for personalized cancer immunotherapy. Expert Opin Drug Deliv. 2023 Mar;20(3):323-333.

9. Wu Y, Guo H, Yue J*, Xu P*. Serum sPD1 and sPDL1 as Biomarkers for Evaluating the Immune State of Lung Adenocarcinoma Patients. J Immunol Res. 2022 Nov 25;2022: 9101912.

10. Wu Y, Shi W, Wang H, Yue J, Mao Y, Zhou W, Kong X, Guo Q, Zhang L, Xu P, Wang Y*. Anti-ST2 Nanoparticle Alleviates Lung Inflammation by Targeting ILC2s-CD4+T Response. Int J Nanomedicine. 2020 Dec 3; 15: 9745-9758.

Email: ymwu@suda.edu.cn